1336 results about "Leukemia" patented technology

A compound of formula (I) or a pharmaceutically acceptable salt or hydrate thereof wherein X-Y is -NHSO2- or -SO2NH-; R1 is H, CN or alkyl; R2 is selected from COOH and a tetrazolyl group; R3 is selected from H, Cl and alkyl; R4 is selected from H and halo; R5 is selected from H, alkyl, haloalkyl, SO2-alkyl, Cl, alkoxy, OH, CN, hydroxyalkyl, alkylthio, heteroaryl, cycloalkyl, heterocycloalkyl and haloalkoxy; R6 is H; R7 is selected from H, CN, haloalkyl, halo, SO2-alkyl, optionally substituted heteroaryl, SO2NR14R15, CONR10R11 and alkyl; R8 is selected from H, alkyl, haloalkyl and halo; R9 is H or halo; and R10, R11, R12, R14, and R15 are H or alkyl; R13 is selected from alkyl, halo, alkoxy, CN, haloalkyl and OH; and m is 0-3. The compounds of formula (I) modulate ERAP1 (endoplasmic reticulum aminopeptidase 1) and are for use in treating proliferative, immune or inflammatory disorders, particularly cancer or leukemia. The compounds of formula (I) stimulate a neo-antigen directed immune response in the subject. A method for producing an antigen-presenting cell which presents a neo-antigen using compounds of formula (I) is disclosed. An immunogenic composition comprising an antigen-presenting cell is also disclosed. Exemplified compounds include 4-cyclopropyl-3-(N-(2-(morpholin-3-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)benzoic acid.

The invention discloses a polypeptide and application thereof in preparation of a medicine for preventing and / or treating cancers. The amino acid sequence of the polypeptide is shown as SEQ ID No. 1 or SEQ ID No. 2. The cancer is at least one of breast cancer, colorectal cancer, leukemia, esophageal cancer, pancreatic cancer, brain glioma, kidney cancer, skin cancer, osteosarcoma, ovarian cancer and prostate cancer. The invention designs and synthesizes the polypeptide of a targeted staphylococcus tumor protein compound SND1-MTDH containing a nuclease structural domain 1 (SND1 and a heteromucin (MTDH), finds that the polypeptide has excellent inhibitory activity on various different types of human cancer cells for the first time, and provides an optional scheme for broad-spectrum anti-cancer drugs. The polypeptide applied in the invention is simple in synthesis process and low in production cost.

The invention discloses a tryptamine compound as well as a preparation method and application thereof. The tryptamine compound can be used for preparing medicines for preventing and / or treating cancers. The cancer is at least one of breast cancer, liver cancer, lung cancer, colorectal cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, cervical cancer, ovarian cancer, kidney cancer and esophageal cancer. According to the invention, activity screening is carried out on a plurality of compounds, the three tryptamine compounds provided by the invention are found to have excellent inhibitory activity on a plurality of different types of human cancer cells for the first time, and an optional scheme is provided for broad-spectrum anti-cancer drugs.

The present invention relates to methods of treatment of acute myeloid leukemia with anti-CD38 antibodies.

The invention relates to the field of natural products, in particular to a dimer compound of guaiane type sesquiterpenes and uric acid as well as an extraction and separation method and application of the dimer compound. According to the invention, a new dimer compound of guaiane type sesquiterpene and uric acid is extracted and separated from carpesium abrotanoides in Guizhou, and it is found that the dimer compound has relatively strong anti-tumor activity. The compound has strong inhibitory activity on breast cancer, prostate cancer, nasopharynx cancer, liver cancer, lung cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, skin cancer, cervical cancer, ovarian cancer, kidney cancer and esophageal cancer, and provides an optional scheme for broad-spectrum anti-cancer drugs. Moreover, in human prostate cancer cells PC3, human cervical cancer cells Hela, human liver cancer cells HepG2 and human glioma cells U87 which are resistant to paclitaxel, the compound also shows strong anti-cancer activity, which indicates that the compound has the potential of treating patients resistant to paclitaxel.

The invention discloses sesquiterpenoids as well as a preparation method and application thereof. The structure of the sesquiterpenoids is shown in the specification. The sesquiterpenoids of # imgabs0 can be used for preparing drugs for preventing and / or treating cancers, and the cancers comprise at least one of breast cancer, liver cancer, lung cancer, colorectal cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, cervical cancer, kidney cancer and skin cancer. According to the invention, various natural product extracts are subjected to activity screening, the sesquiterpenoids derived from the rattan chrysanthemum have excellent inhibitory activity on various different types of human cancer cells, and an optional scheme is provided for broad-spectrum anti-cancer drugs. The sesquiterpenoids applied in the invention are derived from rattan chrysanthemum, the source is wide, and the production cost is low.

The invention belongs to the technical field of chemistry, and particularly relates to a diaryl methyl pyrimidine piperazine compound as well as a preparation method, a pharmaceutical composition and application thereof. The structural formula of the diaryl methyl pyrimidine piperazine compound is shown as a formula I, and R is a substituted aromatic group. The preparation process is simple, the prepared diaryl methyl pyrimidine piperazine compound or the pharmaceutically acceptable salt thereof has the activity of efficiently inhibiting WDR5-MLL 1, and a targeted therapy scheme and novel, safe and efficient candidate drug molecules are provided for treating acute myeloid leukemia with WDR5-MLL fusion mutation. Experimental results show that the tumor inhibition rates of mouse tumor-bearing groups treated by the compounds 5c, 5k and 5l prepared by the invention are 79%, 85% and 75% respectively and are superior to those of a positive control group, and the compounds have good development prospects.

This invention relates to pharmaceutical compositions, pharmaceutical combinations and methods for the treatment of acute myeloid leukemia by combined use of a therapeutically effective combination of a compound of Chemical Formula 1, or a pharmaceutically acceptable salt thereof, solvate thereof, stereoisomer thereof, tautomer thereof, or combination thereof, wherein Ea, Eb, Ec, Ed, Z′, X′, Q, and k are defined herein; and a Bcl-2 inhibitor, or a Bcl-2 inhibitor and a hypomethylating agent.

The invention provides a VEGFR2-HDAC6 dual inhibitor containing chalcone fragments as well as a preparation method and application of the VEGFR2-HDAC6 dual inhibitor, and relates to the technical field of medicinal chemistry. The invention discloses a VEGFR2-HDAC6 dual inhibitor containing chalcone fragments. The structural formula of the VEGFR2-HDAC6 dual inhibitor is shown as a formula A, according to the invention, the VEGFR2-HDAC6 dual inhibitor containing the chalcone fragment and having a novel structure is designed and synthesized by utilizing a splicing principle, the anti-proliferative activity test is carried out on cervical cancer cells Siha and chronic granulocytic leukemia cells K562, and the result shows that the VEGFR2-HDAC6 dual inhibitor containing the chalcone fragment provided by the invention has relatively good inhibitory activity on the Siha cells and the K562 cells.

According to the invention, the primers are designed for 65 leukemia fusion genes through sufficient literature investigation in the early stage, the leukemia genotypes covering 90% or more are covered, and the primers are good in amplification performance and strong in specificity; based on a multiple digital PCR system of an innovative multicolor fluorescent channel, different fluorescently-labeled hydrolysis probes are designed, multi-gene multi-channel detection is combined, 65 leukemia fusion genes are detected at the same time, leukemia typing can be judged through one-time detection, and time is saved. Through high-throughput detection, the cost is reduced to 1 / 10 of that of foreign like products, and the sensitivity is high.

The invention discloses a hybridoma cell strain, a monoclonal antibody, a linear epitope antigen and application thereof, and relates to the field of genetic engineering, in particular to a hybridoma cell strain, a monoclonal antibody, a linear epitope antigen and application thereof. The preservation number of the hybridoma cell strain P27-A1 is CGMCC (China General Microbiological Culture Collection Center) No. 46352. The hybridoma cell strain P27-A1 is prepared from feline leukemia virus p27, and a monoclonal antibody secreted by the hybridoma cell strain P27-A1 recognizes a linear epitope antigen of feline leukemia virus p27 protein; the kit for the feline leukemia virus p27 comprises the monoclonal antibody A1 secreted by the hybridoma cell strain P27-A1. The monoclonal antibody secreted by the hybridoma cell strain can greatly improve the sensitivity of the p27 protein for detecting feline leukemia virus. The invention provides the monoclonal antibody secreted by the hybridoma cell strain for identification, and the monoclonal antibody can be used for preparing a diagnostic kit such as a colloidal gold test strip.

The present invention relates to the use of a combination of two different cannabinoids in the treatment of leukaemia. The combination of CBD with THC appears to be particularly effective in reducing cell number in this disease. Preferably the cannabinoids are used in the form of an extract of Cannabis such that many of the naturally occurring compounds are co-extracted with the THC or CBD. Alternatively, the cannabinoids are present in the form of a highly purified extract of Cannabis, wherein the CBD or THC are present at greater than 98% of the total extract (w / w) and the other components of the extract are characterized. Alternatively, the CBD and THC may be synthetically produced. A specific ratio of CBD and THC such as 10:1 to 1:10 (CBD:THC) or more preferably between 2:1 to 1:2 (CBD:THC) may be used.

The invention relates to the field of molecular targeted therapy, and discloses an application of an SLC16A5 (MCT6) small-molecule inhibitor MCT6-Ai7-2 in preparation of a medicine for treating acute myeloid leukemia (AML). The inhibitor takes an SLC16A5 protein structure predicted by Alphafold as a target spot, and is obtained through compound database screening, molecular docking and druggability optimization. An in-vitro experiment proves that MCT6-Ai7-2 can remarkably inhibit proliferation of AML cell lines such as U937 and MOLM-13, induce cell apoptosis and retard a cell cycle, has an inhibiting effect on a primary AML patient specimen and is relatively low in toxicity to normal cells; in-vivo experiments show that the compound is effective and has good safety in AML model mice. In addition, the MCT6-Ai7-2 and the vinca can be combined to synergistically enhance the inhibition effect on vinca drug-resistant cells, and by reducing the expression of anti-apoptotic protein MCL-1, the activation of pro-apoptotic factors BIM and tBID is promoted to play a role. The invention provides a novel targeting drug and strategy for treatment of AML (especially drug-resistant or recurrent patients).

The invention belongs to the technical field of immunoassay and biosensing, and provides a novel construction mode of a heterojunction dual-photoelectrode photoelectric sensing strategy and a preparation method of an in-situ heterojunction MIO photocathode. The invention relates to a preparation method of a heterojunction dual-photoelectrode type photoelectrochemical sensor based on multi-ball cascade DNA reaction amplification. Specifically, the design is composed of an In2O3 / CdS photoanode and an in-situ formed MIL-68 / In2O3 (MIO) photocathode. The heterojunction dual-photoelectrode sensing strategy effectively prolongs an electron-hole transmission path, enhances photo-generated charge separation, and realizes' super-open 'PEC signal output, thereby providing a steady baseline for signal conversion. Meanwhile, a multi-sphere cascade DNA reaction is combined to output a three-dimensional DNA net structure to provide a large number of sites for embedding of a PEC quenching probe doxorubicin-ferrocene carboxylic acid (DOX-FcCOOH), obvious PEC signal quenching is realized by utilizing the efficient competitive electron transfer capability of the three-dimensional DNA net structure, and finally, a signal conversion system with'opening-super opening-closing 'multistage response characteristics is constructed. The detection of the nucleic acid marker Pax-5a gene of the B cell acute lymphatic leukemia is realized by detecting target objects with different concentrations.

The invention discloses a kit and method for detecting leukemia and lymphoma based on full-spectrum flow cytometry, the kit comprises 25 antibodies, the antibodies are specifically bound with fluorescein respectively, and leukemia and lymphoma are detected through full-spectrum flow cytometry; the 25 kinds of antibodies comprise HLA-DR (human leukocyte antigen-DR), CD38, CD7, CD34, Lambda, CD19, CD64, CD14, CD5, CD123, CD16, CD20, Kappa, CD117, CD13, CD45, CD11b, CD2, CD10, CD8, CD15, CD4, CD3, CD56 and CD33. The kit comprehensively covers development stages of various lines of bone marrow cells, and common abnormal expressions of various leukemia, myelodysplastic syndromes and lymphoma, and can preliminarily screen various leukemia and lymphoma.

This invention relates to the field of anticancer drugs, and more particularly to an indole-3-aryl ketone derivative, its preparation method, and its applications. The indole-3-aryl ketone derivative is compound I-VI, which can be used to prepare drugs for the prevention and / or treatment of cancer, including at least one of breast cancer, liver cancer, lung cancer, colorectal cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, cervical cancer, ovarian cancer, kidney cancer, and esophageal cancer. This invention screened the activity of various compounds and, for the first time, discovered that compound I-VI exhibits excellent inhibitory activity against multiple different types of human cancer cells, providing a potential option for broad-spectrum anticancer drugs.

The invention provides an in-vitro skin blood vessel immune model as well as a preparation method and application thereof. THP-1 human monocyte leukemia cells are induced to be differentiated into M0 type macrophages, and then the M0 type macrophages are respectively induced into M1 type macrophages and / or M2 type macrophages; then co-culturing the M1 type and / or M2 type macrophages and vascular endothelial cells to form a vascular immune model; finally, the 3D skin model is placed on the blood vessel immune model, external stimulation is conducted, and the in-vitro skin blood vessel immune model is constructed. The in-vitro skin blood vessel immune model can be used for repairing skin barriers, inflammation pathways, blood vessel metabolism, the expression level of genes or proteins related to extracellular matrixes, vascular endothelial cells, the proliferation and migration ability of activated macrophages and the like. The seven feature dimensions of the physiological structure feature of the skin model are used for screening the to-be-tested sample and exploring the action mechanism, and the method has the characteristics of rapidness, multiple screening dimensions, high accuracy, low construction difficulty, low cost and high universality.

The invention discloses a leukemia targeted therapy preparation as well as a preparation method and application thereof. Comprising a DNA nanoflower carrier targeting leukemia cells through a PTK7 receptor and benzene arsenic oxide loaded on the carrier. The DNA nanoflower carrier is obtained by rolling circle amplification, and a nucleic acid aptamer complementary sequence of targeted binding leukemia cells is introduced into a template chain subjected to rolling circle amplification. The preparation method comprises the following steps: modifying sulfydryl onto a DNA nanoflower by using DNA-Dithiol, then breaking a disulfide bond by using reduced glutathione to expose the sulfydryl, and loading benzene arsenic oxide onto the DNA nanoflower through a reaction between trivalent arsenic and the sulfydryl. The structure of the DNA nanoflower has a high surface area and high porosity, and can load a large amount of PAO, so that the killing performance on cancer cells is enhanced; the aptamer sgc8 sequence is introduced into the DNA nanoflower, so that the targeting of the DNA nanoflower to cancer cells is effectively realized; the preparation also has the advantages of being good in thermodynamic stability, easy to store, excellent in biocompatibility and the like, and has a very good application prospect.

An antibody capable of binding to LILRB4 and a bispecific antibody capable of binding to LILRB4 and CD3 are provided. Nucleic acid molecules encoding the antibodies, expression vectors, host cells and methods for expressing the antibodies are also provided. Also provided are methods of treating solid tumors, multiple myeloma or leukemia, such as acute myelogenous leukemia (AML), using the anti-LILRB4xCD3 double antibodies of the present invention.

The invention discloses an application of a tetrahydroisoquinoline compound in preparation of an anti-leukemia drug. The compound has a remarkable inhibition effect on leukemia cells, has low toxicity to organisms, not only expands the variety of drugs for clinical treatment of leukemia, but also is suitable for large-scale production.

The invention relates to the technical field of pharmaceutical preparations, and particularly discloses a cyclophosphamide ternary nano-micelle and a preparation method thereof.The cyclophosphamide ternary nano-micelle prepared through the method can be used for treating malignant lymphoma, multiple myeloma, leukemia, breast cancer, ovarian cancer, cervical cancer, prostatic cancer, colon cancer, bronchial cancer, lung cancer and the like. Reasonable preparation steps and a preparation formula are adopted, the use of an organic reagent is reduced, the irritation of cyclophosphamide is reduced and the stability of the micelle is improved by adjusting a freeze-drying technology, and the cyclophosphamide micelle adopts amphiphilic macromolecules as a carrier material, so that the drug loading capacity and the stability of the micelle are obviously improved, and the bioavailability of the micelle is improved. The ternary nano-micelle system has the advantages that the solubility of cyclophosphamide is improved, the in-vivo bioavailability is increased, the preparation method is simple, the micelle performance is stable, and large-scale industrial production is facilitated.

The invention relates to the technical field of natural compounds, in particular to ganoderma leukemia polysaccharide and a preparation method thereof. The ganoderma leukemia polysaccharide comprises galactose, glucose and mannose, and the molar ratio of the galactose to the mannose to the glucose is (1.5-3.5): (15-30): (65-85); the ganoderma leukemia polysaccharide comprises:-> 6)-Glcp-(1-> dominant residues; (-> 6)-Manp-(1->,-> 4)-Glcp-(1-> residue; and-> 4, 6)-Manp-(1->,-> 3, 6)-Galp-(1->. The ganoderma leukemia polysaccharide has anti-oxidation and detoxification capabilities, can avoid neurodegenerative diseases, reduce lipid accumulation and prolong the service life, and also has high-temperature resistance.

The invention relates to the technical field of electrocardiosignal detection, in particular to a leukemia child cardiotoxicity prediction system based on electrocardio dynamic evolution characteristics, which comprises the following steps: acquiring electrocardiosignals of a leukemia child in a whole chemotherapy cycle; performing empirical mode decomposition on the preprocessed electrocardiosignal, and performing dynamic modeling on an empirical mode decomposition result to obtain time domain representation and dynamic domain representation under different scales; performing cross-domain fusion on the time domain representation and the dynamic domain representation under different scales to obtain multi-scale dynamic and static characteristics; on the basis of the multi-scale dynamic and static characteristics, electrocardio time-varying dynamic evolution characteristics of the child patient in the whole chemotherapy period are calculated; based on the electrocardio time-varying dynamic evolution characteristics of the whole chemotherapy cycle of the child patient, predicting an early prediction result of cardiotoxicity of the child patient; and explaining the prediction result to obtain the causal relationship between the cardiotoxicity and the electrocardio time-varying dynamic evolution characteristics. And the accuracy of cardiac toxicity prediction is improved.

The invention provides application of macrophage PHGDH in preparation of a TAK1 inhibitor, and belongs to the technical field of biological medicine. The invention finds that the PA-induced inflammation can be promoted by knocking down the PHGDH in the macrophage. In addition, the macrophage specific PHGDH is combined with TAK1, and the interaction between TAK1 and TAB1 is inhibited, so that the activation of TAK1 and downstream NF-kB and MAPK signal transduction are inhibited. Development of metabolic dysfunction related steatohepatitis MASH caused by medullary system PHGDH knockout can be slowed down by inhibiting TAK1 activation. What's more important is that the MAFLD is reduced by the overexpression of the PHGDH in the adeno-associated virus mediated liver macrophages. The invention discovers that the macrophage PHGDH is a promising medicine for treating MAFLD (MAFF-induced leukemia disease).

The invention discloses a limonin compound and application thereof in preparation of a medicine for preventing and / or treating cancers. The structure of the limonin compound is shown as a formula I or II. The cancer is at least one of breast cancer, liver cancer, gastric cancer, esophageal cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, prostatic cancer, nasopharynx cancer, cervical cancer, ovarian cancer, kidney cancer and skin cancer. According to the invention, activity screening is carried out on various natural product extracts, it is found for the first time that limonin compounds with structural formulas I and II have excellent inhibitory activity on various different types of human cancer cells, and an optional scheme is provided for broad-spectrum anti-cancer drugs. Related results also show that the compound provided by the invention can inhibit migration and invasion ability of breast cancer cells, promote cell apoptosis and retard a cell cycle. The limonin compound applied in the invention is derived from mallotus oblongifolius, the source is wide, and the production cost is low.

The invention discloses a novel polypeptide, a polypeptide derivative and application thereof, and belongs to the technical field of biological medicine. The invention specifically relates to a specific sequence, a discovery process, a specific anti-tumor type, a long-acting modification mode and application of the novel polypeptide. The tumors comprise one or more of brain glioma, neuroblastoma, head and neck cancer, esophagus cancer, thyroid cancer, lung cancer, liver cancer, kidney cancer, breast cancer, cervical cancer, uterine cancer, ovarian cancer, colon cancer, small intestinal cancer, ileocecum cancer, stomach cancer, bladder cancer, pancreatic cancer, prostate cancer, bile duct cancer, melanoma, sarcoma, myeloma, lymphoma and leukemia; the compound has the specific effect of inhibiting proliferation and / or metastasis of tumor cells, is wide in treatment spectrum and has important treatment value in various tumors.

The invention discloses an application of EIF5B in treatment of leukemia. According to the application, the translation initiation factor EIF5B which is generally highly expressed in various subtype AML patients is found for the first time, specifically participates in maintaining the function of an AML cell line, does not influence the function of normal HSPC, and is expected to become a broad-spectrum AML treatment target.

The invention belongs to the technical field of indication viruses, and particularly relates to a method for improving mouse leukemia virus titer and / or stability. The invention provides an application of mifepristone in improving mouse leukemia virus titer and / or stability. The mifepristone is utilized to integrate the mouse leukemia virus onto the cell genome, so that the amplification of the mouse leukemia virus is completed, the infection efficiency of the mouse leukemia virus is improved, and finally the mouse leukemia virus stock solution with higher titer and better stability is obtained.

The invention relates to the field of anti-cancer drugs, in particular to an indole-3-aryl ketone derivative as well as a preparation method and application thereof. The indole-3-aryl ketone derivative is a compound I-VI, the indole-3-aryl ketone derivative can be used for preparing drugs for preventing and / or treating cancers, and the cancers comprise at least one of breast cancer, liver cancer, lung cancer, colorectal cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, cervical cancer, ovarian cancer, kidney cancer and esophageal cancer. According to the invention, activity screening is carried out on various compounds, the fact that the compounds I-VI have excellent inhibitory activity on various different types of human cancer cells is found for the first time, and an optional scheme is provided for broad-spectrum anti-cancer drugs.

The invention discloses an antibody combination and a system for detecting leukemia stem cells. The antibody combination comprises a CD7 antibody, a CD371 antibody, a CD34 antibody, a CD45RA antibody, a CD123 antibody, a CD133 antibody, a CD38 antibody, a CD45 antibody, a CD90 antibody, a CD33 antibody and a CD19 antibody. The antibody combination provided by the invention can accurately identify target cells and distinguish normal HSCs and pluripotent progenitor cells in a CD34 + CD38-cell population, and the specific antibody has abnormal expression or expression intensity change, so that leukemia stem cells can be rapidly, simply and conveniently detected with high accuracy, high sensitivity and high specificity, the sensitivity of MRD evaluation is favorably improved, and the kit has a good application prospect. Therefore, signs of disease recurrence can be found earlier, more information about disease prognosis can be provided, and doctors and patients can be helped to better understand disease prognosis and possible results.